TORONTO, Aug. 11, 2026 /CNW/ -- DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced that it has received the Put Price of approximately US$178 million in connection with its previously announced exercise of the contractual put option with respect to its royalty participation right in EKTERLY (the "Put Option").
As previously announced on July 10, 2026, DRI Healthcare exercised the Put Option following the completion of Chiesi Group's acquisition of KalVista Pharmaceuticals, Inc. Receipt of the Put Price completes the transaction, and DRI Healthcare's royalty participation right in EKTERLY has accordingly terminated.
"We are pleased to have completed the transaction and appreciate Chiesi's collaboration throughout the process," said Ali Hedayat, Chief Executive Officer of DRI Healthcare. "This outcome reflects our disciplined underwriting and creates additional capacity to pursue attractive opportunities for our Unitholders."
About DRI Healthcare
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the TSX in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". To learn more, visit drihealthcare.com or follow us on LinkedIn.
Caution concerning forward-looking statements
This news release may contain forward-looking information within the meaning of applicable securities legislation including statements regarding the expected use of proceeds, and DRI Healthcare's future investment activities. Forward-looking information can generally be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond DRI Healthcare's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties are disclosed in DRI Healthcare's most recent annual information form and under "Risk Factors" in DRI Healthcare's Management's Discussion and Analysis. You should not put undue reliance on forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, the actual results, performance or achievements of DRI Healthcare could differ materially from the results expressed in, or implied by, any forward-looking statements. All forward-looking information in this news release speaks as of the date of this news release. DRI Healthcare does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in DRI Healthcare's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at DRI Healthcare's website at drihealthcare.com/investors.
For further information, please contact:
Bill Zhang
Head of Investor Relations
ir@drihealthcare.com
SOURCE DRI Healthcare Trust
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2026/11/c3873.html